Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.

Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.

The purpose of the present study was to develop and assess a novel sustained-release drug delivery system of Bimatoprost (BIM). Chitosan polymeric inserts were prepared using the solvent casting method and characterized by swelling studies, infrared spectroscopy, differential scanning calorimetry, d...

Full description

Bibliographic Details
Main Authors:	Juçara Ribeiro Franca, Giselle Foureaux, Leonardo Lima Fuscaldi, Tatiana Gomes Ribeiro, Lívia Bomfim Rodrigues, Renata Bravo, Rachel Oliveira Castilho, Maria Irene Yoshida, Valbert Nascimento Cardoso, Simone Odília Fernandes, Sebastião Cronemberger, Anderson José Ferreira, André Augusto Gomes Faraco
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4005758?pdf=render

Similar Items

Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats.
by: Giselle Foureaux, et al.
Published: (2015-01-01)

Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients
by: Nicholas Brennan, et al.
Published: (2017-08-01)

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
by: Xu KM, et al.
Published: (2022-07-01)

Ocular Delivery of Bimatoprost-Loaded Solid Lipid Nanoparticles for Effective Management of Glaucoma
by: Sandeep Divate Satyanarayana, et al.
Published: (2023-07-01)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
by: Inoue K, et al.
Published: (2012-01-01)

Comparison of the Efficacy of Latanoprost, Bimatoprost, and Travoprost in Patients with Primary Open-Angle Glaucoma and Ocular Hypertension
by: Nur Çolak, et al.
Published: (2014-05-01)

Bimatoprost/timolol fixed combination (BTFC) in patients with primary open angle glaucoma or ocular hypertension in Greece
by: Tryfon G. Rotsos, et al.
Published: (2016-01-01)

Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]
by: Galambos Peter, et al.
Published: (2005-04-01)

Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment
by: Gerrett Brief, et al.
Published: (2010-09-01)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
by: Pillunat LE, et al.
Published: (2016-09-01)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
by: Shafiee A, et al.
Published: (2013-07-01)

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
by: Mariaelena Filippelli, et al.
Published: (2022-06-01)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
by: Lee D, et al.
Published: (2017-07-01)

Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes
by: Figueiredo BP, et al.
Published: (2013-08-01)

Bimatoprost in dermatology
by: Abhijeet K Jha, et al.
Published: (2018-01-01)

Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol in Glaucoma and Ocular Hypertension in India: A Multicenter, Open-Label, Phase 3 Study
by: Menon MG, et al.
Published: (2022-10-01)

Glaucoma: Past, Present, and Future
by: Sebastião Cronemberger
Published: (2020-11-01)

Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better?
by: Georgios S. Dimtsas, et al.
Published: (2023-10-01)

Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways.
by: Xiaohong Li, et al.
Published: (2016-01-01)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
by: Scott D Smid
Published: (2009-11-01)

Comparison of safety and efficacy of Netarsudil 0.02% and Bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension
by: Saima Shahid, et al.
Published: (2024-01-01)

The efficiency of monotherapy of patients with primary open-angle glaucoma with Bimatoprost 0.03 % (Bimoptic)
by: S. A. Korotkikh, et al.
Published: (2018-12-01)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
by: Inoue K, et al.
Published: (2014-06-01)

An observational study of bimatoprost 0.01% in treatment-na&iuml;ve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
by: Nixon DR, et al.
Published: (2012-12-01)

Ceratoplastia penetrante e glaucoma Penetrating keratoplasty and glaucoma
by: Márcio Eulálio Barreto Soares, et al.
Published: (2007-08-01)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
by: Moataz E Gheith, et al.
Published: (2008-03-01)

Phase 3, Randomized Study Comparing Intracameral Bimatoprost Implant 15 μg and Selective Laser Trabeculectomy in Patients with Open-Angle Glaucoma or Ocular Hypertension
by: Christie WC, et al.
Published: (2023-10-01)

A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension
by: Pfennigsdorf S, et al.
Published: (2013-06-01)

Malignant glaucoma
by: Sebastião Cronemberger, et al.
Published: (2012-10-01)

Efficacy of Monotherapy with Either Bimatoprost or Travoprost in Patients with Primary Open-Angle Glaucoma Resistant to Latanoprost Therapy
by: Yusuf Koçluk, et al.
Published: (2011-10-01)

DESENVOLVIMENTO E VALIDAÇÃO DE MÉTODO ANALÍTICO ESPECTROFOTOMÉTRICO PARA QUANTIFICAÇÃO DE NEROLIDOL EM UM DISPOSITIVO POLIMÉRICO DE LIBERAÇÃO PROLONGADA, APÓS DERIVATIZAÇÃO COM VANILINA
by: Tatiana Gomes Ribeiro, et al.
Published: (2018-04-01)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
by: Chang-Lin J-E, et al.
Published: (2011-08-01)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
by: Stevens A, et al.
Published: (2016-04-01)

Management of hypotrichosis of the eyelashes: Focus on bimatoprost
by: Steven Fagien
Published: (2010-04-01)

Design and evaluation of guargum - based timolol maleate ocular insert For the treatment of glaucoma
by: Sunil Thakral
Published: (2015-12-01)

Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China
by: Sun XH, et al.
Published: (2017-04-01)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
by: Tsumura T, et al.
Published: (2013-07-01)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
by: Pfennigsdorf S, et al.
Published: (2016-09-01)

Development and validation of analytical method by HPLC-DAD for determination of vasodilator active in pharmaceutical ophthalmic forms
by: Aina Liz Alves Cesar, et al.
Published: (2020-08-01)

PRESERVATIVE-FREE FIXED COMBINATION OF BIMATOPROST AND TIMOLOL IN THE EVOLUTION OF COMPLIANCE AND TREATMENT EFFECTIVENESS IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA
by: I. A. Loskoutov, et al.
Published: (2018-10-01)